FDA Bars Drug Importer for Five Years Over Bad Labels
Published Date: 9/19/2025
Notice
Summary
William Goldsmith is banned for 5 years from importing any drugs into the U.S. because he was convicted of selling mislabeled drugs. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban is official starting August 19, 2025. This means no drug imports from him for half a decade, protecting consumers from unsafe products.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Individual banned from importing drugs
William Goldsmith is barred for 5 years from importing or offering for import any drug into the United States, effective August 19, 2025. FDA based the order on his conviction of one felony count for introducing misbranded drugs into interstate commerce. Mr. Goldsmith did not respond to the FDA's notice or request a hearing, and his failure to respond waived his right to a hearing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
Previous / Next Documents
Previous: 2025-18212 — Agency Information Collection Activities; Submission for OMB Review; Comment Request, Employment Transition Models Demonstration and Evaluation, New Collection
The Department of Labor is asking for feedback on a new survey about how people move from one job to another. This helps make sure the questions are clear and don’t take too much time or money to answer. If you’re involved in job programs or studies, your input matters before the final rules are set.
Next: 2025-18214 — Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Big banks like PNC want to buy or merge with other banks, like FirstBank in Colorado. The Federal Reserve is checking these deals to make sure they follow the rules and wants your comments by October 20, 2025. These changes could shake up who controls local banks and might affect how money moves around.